Matthew R. Zibelman

机构：Fox Chase Cancer Center, Temple University Health System · ORCID：0000-0003-1475-6477

发表论文 269 篇 · 总被引 2529 次 · h-index 29

代表论文

• Circulating tumor DNA (ctDNA) to guide response-adapted bladder preservation in muscle invasive bladder cancer (MIBC): Integrated analysis of the RETAIN trials. (2026 · Journal of Clinical Oncology · 被引 7)
• Perioperative Immune-Checkpoint Inhibition in Renal Cell Carcinoma: Lessons Learned and Future Directions (2026 · Cancers · 被引 3)
• Assessing Treatment Outcomes of Patients Undergoing Enfortumab Vedotin Dose Reduction in Metastatic Bladder Cancer (2026 · Clinical Genitourinary Cancer · 被引 1)
• Advancements in Bladder-Sparing Strategies for Muscle-Invasive Bladder Cancer (2026 · Urologic Clinics of North America)
• Clinical Outcomes of Metastatic Urothelial Carcinoma Patients Discontinuing Enfortumab Vedotin Due to Toxicity and/or Clinical Response (2026 · Clinical Genitourinary Cancer)
• A phase II trial of neoadjuvant zanzalintinib (ZANZA) plus nivolumab (NIVO) in patients with locally advanced and/or surgically challenging clear cell renal cell carcinoma (EXPLORE-RCC). (2026 · Journal of Clinical Oncology)